Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Bas M. Bavelaar"'
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
The last decade has seen rapid growth in the use of theranostic radionuclides for the treatment and imaging of a wide range of cancers. Radionuclide therapy and imaging rely on a radiolabeled vector to specifically target cancer cells. Radionuclides
Externí odkaz:
https://doaj.org/article/ec1945208c5043c9a55d886982c00631
Autor:
Katherine A. Vallis, Madalena Tarsounas, Tom Brown, Afaf H. El-Sagheer, Martin R. Gill, Philip A. Waghorn, Bas M. Bavelaar, Mark R. Jackson
Telomerase is expressed in the majority (>85%) of tumors, but has restricted expression in normal tissues. Long-term telomerase inhibition in malignant cells results in progressive telomere shortening and reduction in cell proliferation. Here we repo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e28019c487d490888c1e3a57acc17d76
https://doi.org/10.1158/0008-5472.c.6511004.v1
https://doi.org/10.1158/0008-5472.c.6511004.v1
Autor:
Katherine A. Vallis, Madalena Tarsounas, Tom Brown, Afaf H. El-Sagheer, Martin R. Gill, Philip A. Waghorn, Bas M. Bavelaar, Mark R. Jackson
The supplementary data file contains mass spectrometry (MS) and size exclusion chromatography (SEC) data to confirm DTPA-, 111In-, and fluorophore-labeling of oligonucleotides, TRAP assay control experiments, quantification of fluorophore-oligonucleo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03923d9e8b7d739f4dcdf22d1291c251
https://doi.org/10.1158/0008-5472.22421717.v1
https://doi.org/10.1158/0008-5472.22421717.v1
Autor:
Ole Tietz, Philip A. Waghorn, Robert Carlisle, Mark R. Jackson, Lei Song, Martin R. Gill, Irini Skaripa-Koukelli, Madalena Tarsounas, Bas M. Bavelaar, Sarah Able, Katherine A. Vallis
Publikováno v:
Molecular Pharmaceutics
Telomerase represents an attractive target in oncology as it is expressed in cancer but not in normal tissues. The oligonucleotide inhibitors of telomerase represent a promising anticancer strategy, although poor cellular uptake can restrict their ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc6ba5b5cd67a99da8a217626dd2550
https://ora.ox.ac.uk/objects/uuid:ef1fdf06-d47c-4d62-b7f0-c056d58b0ace
https://ora.ox.ac.uk/objects/uuid:ef1fdf06-d47c-4d62-b7f0-c056d58b0ace
Autor:
Martin R. Gill, Madalena Tarsounas, Afaf H. El-Sagheer, Philip A. Waghorn, Tom Brown, Mark R. Jackson, Bas M. Bavelaar, Katherine A. Vallis
Publikováno v:
Cancer Res
Telomerase is expressed in the majority (>85%) of tumors, but has restricted expression in normal tissues. Long-term telomerase inhibition in malignant cells results in progressive telomere shortening and reduction in cell proliferation. Here we repo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052176eab241ce5c3a5f29dd4713450f
https://cronfa.swan.ac.uk/Record/cronfa52920
https://cronfa.swan.ac.uk/Record/cronfa52920